Tag: Medicare Part D
Expenditures are high and projected to rise because national healthcare costs are out of control. The 2024 Medicare Trustees Report (released this spring) got almost no attention, contained no bad news. It is true that, under current law, Medicare Part A – the Hospital Insurance (HI) program – faces a long-term deficit, but that deficit…
The drug companies want $26,500 per year for the newest Alzheimer’s drug; negotiations might take it to $20,000. The potential for full Food and Drug Administration approval of the new Biogen-Esai Alzheimer’s drug (Leqembi) means that Medicare may make the drug available to beneficiaries. The $26,500 annual price tag associated with Leqembi will wreak havoc wit…
